2023.06.07 Uliledlimab and toripalimab combination therapy in treatment-naïve advanced NSCLC: Phase 1b/2 clinical trial results using CD73 as a potential predictive biomarker
2022.11.10 Revealing Novel Immune Modulatory Mechanism of Uliledlimab through the Blockade of CD73 Pathway
2022.06.07 The safety, pharmacokinetics (PK), pharmacodynamics (PD) and clinical efficacy of uliledlimab, a differentiated CD73 antibody, in combination with atezolizumab in patients with advanced cancer
